The large EPS miss on a minimal base is a mechanical artifact and not a reflection of business deterioration, the key driver is commercial execution on Ryoncil. Watch for continued revenue growth updates from major U.S. pediatric centers. The cross-filing activist context amplifies pressure, making any positive revenue updates more impactful.
Drugs in focus
MESO drug pipeline →rexlemestrocel-L
▲ Bullish Named in this press release- Impact
- Phase
- Phase 3 / Filed BLA
- Time to market
- LVAD/heart failure BLA now under FDA review with modular review requested — no PDUFA date set yet (potentially 2027 if accepted). CLBP indication likely 2028 at earliest (topline mid-2027, BLA Q3 2027, FDA action 2028).
- Next catalyst
- None dated
What to watchMesoblast just filed a BLA for rexlemestrocel-L in LVAD/heart failure, the next catalyst is FDA acceptance and a PDUFA date. Meanwhile, the much larger CLBP opportunity (7M+ US patients, non-opioid approach) is advancing with Phase 3 enrollment complete and topline due mid-2027. The company already generates real revenue from Ryoncil (~$110-120M FY2026 guidance), de-risking the story vs. pre-revenue biotechs. Monitor (1) FDA's action on the LVAD BLA modular review, (2) CLBP Phase 3 topline in mid-2027, and (3) Ryoncil revenue growth trajectory.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 10 $15.44entry
- T+1 · 4mo ago +5.05%α +5.82% · $16.22
- T+5 · 4mo ago +15.67%α +16.23% · $17.86
- T+20 · 3mo ago +3.24%α +0.81% · $15.94
- T+60 · 6w ago −7.90%α −10.53% · $14.22
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Mesoblast reported Q1 FY2026 EPS of -$0.07, missing consensus of -$0.03 by 133%. However, the company announced full-year Ryoncil net revenue of $115M, exceeding initial projections, with continued growth expected. The EPS miss is on a tiny base and the Ryoncil revenue narrative is the dominant driver, making the overall tone mixed.
Key Financial Metrics
Key Facts
- FY2026 Q1 EPS: -$0.07, -133% miss vs consensus -$0.03.
- Ryoncil net revenue of US$36M for Q1 FY2026 and US$115M for full year ended June 30, 2026.
- CEO stated revenue exceeded initial projections and anticipates continued growth.
Financial Impact
Revenue of $115M for FY2026, exceeding projections; EPS of -$0.07 vs -$0.03 estimate.
Risk Factors
- Ryoncil revenue growth may not sustain the initial launch momentum.
- Reliance on a single product for near-term revenue.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3325284 |
Track record
25 reports on MESO
7 of 15 bullish or bearish reports moved the stock their way by T+1. Best: +24.95% at T+20 after the Jul 30, 2026 report. 10 of 15 went positive at some point.
Filters
- Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
- Nov 10, 20266d ago 6-K Neutral 3/10 Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
- Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
- Oct 29, 202618d ago 6-K Bullish 6/10 No price data
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
- Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
- Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
- Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
- Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
- Aug 27, 202611w ago 20-F Bullish 6/10 Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers